Clover Health (CLOV) executive sells 2,360 shares in 10b5-1 plan
Rhea-AI Filing Summary
Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, sold 2,360 shares of Class A common stock in an open-market transaction at a weighted average price of $4.78 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.
After this sale, Reynoso directly holds 2,841,211 Clover Health shares, so the transaction represents a very small portion of her overall stake.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 2,360 shares ($11,281)
Net Sell
1 txn
Insider
Reynoso Jamie L.
Role
CEO, Medicare Advantage
Sold
2,360 shs ($11K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 2,360 | $4.78 | $11K |
Holdings After Transaction:
Class A Common Stock — 2,841,211 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Shares sold: 2,360 shares
Sale price: $4.78 per share
Post-transaction holdings: 2,841,211 shares
+2 more
5 metrics
Shares sold
2,360 shares
Open-market sale of Class A Common Stock
Sale price
$4.78 per share
Weighted average sale price for the transaction
Post-transaction holdings
2,841,211 shares
Direct ownership after the reported sale
Transaction code
S
Open-market or private sale of non-derivative securities
Trading plan adoption date
March 12, 2026
Date Rule 10b5-1 trading plan was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Class A Common Stock, open-market sale
4 terms
Rule 10b5-1 trading plan regulatory
"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Class A Common Stock financial
"security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Clover Health (CLOV) executive Jamie L. Reynoso report in this Form 4?
Jamie L. Reynoso reported selling 2,360 shares of Clover Health Class A common stock. The transaction was an open-market sale executed under a Rule 10b5-1 trading plan, reflecting routine portfolio activity rather than a large change in ownership.
Was the Clover Health (CLOV) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the sale was effected under a Rule 10b5-1 trading plan adopted on March 12, 2026. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary market-timing decisions by company insiders.